Recent Update on Bacteria as a Delivery Carrier in Cancer Therapy: From Evil to Allies.
bacteria-assisted therapy
cancer treatment
drug delivery
therapeutic carrier for chemotherapy
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
11
11
2021
accepted:
18
03
2022
pubmed:
8
4
2022
medline:
18
6
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
Cancer is associated with a comprehensive burden that significantly affects patient's quality of life. Even though patients' disease condition is improving following conventional therapies, researchers are studying alternative tools that can penetrate solid tumours to deliver the therapeutics due to issues of developing resistance by the cancer cells. Treating cancer is not the only the goal in cancer therapy; it also includes protecting non-cancerous cells from the toxic effects of anti-cancer agents. Thus, various advanced techniques, such as cell-based drug delivery, bacteria-mediated therapy, and nanoparticles, are devised for site-specific delivery of drugs. One of the novel methods that can be targeted to deliver anti-cancer agents is by utilising genetically modified non-pathogenic bacterial species. This is due to the ability of bacterial species to multiply selectively or non-selectively on tumour cells, resulting in biofilms that leads to disruption of metastasis process. In preclinical studies, this technology has shown significant results in terms of efficacy, and some are currently under investigation. Therefore, researchers have conducted studies on bacteria transporting the anti-cancer drug to targeted tumours. Alternatively, bacterial ghosts and bacterial spores are utilised to deliver anti-cancer drugs. Although in vivo studies of bacteria-mediated cancer therapy have shown successful outcome, further research on bacteria, specifically their targeting mechanism, is required to establish a complete clinical approach in cancer treatment. This review has focused on the up-to-date understanding of bacteria as a therapeutic carrier in the treatment of cancer as an emerging field.
Identifiants
pubmed: 35386012
doi: 10.1007/s11095-022-03240-y
pii: 10.1007/s11095-022-03240-y
pmc: PMC8985562
doi:
Substances chimiques
Antineoplastic Agents
0
Excipients
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1115-1134Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience [Internet]. 2019 [cited 2021 Nov 2];13:961. Available from: /pmc/articles/PMC6753017/.
Cao Z, Liu J. Bacteria and bacterial derivatives as drug carriers for cancer therapy. J Control Release. 2020;326:396–407.
doi: 10.1016/j.jconrel.2020.07.009
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Heal [Internet]. 2016 [cited 2021 Nov 2];4(9):e609–16. Available from: https://pubmed.ncbi.nlm.nih.gov/27470177/
Papadakis MA, McPhee SJ, editors. Current Medical Diagnosis & Treatment [Internet]. 40th ed. New York: McGraw Hill Medical; 2021 [cited 2021 Nov 2]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2957§ionid=249359850
Nallar SC, Xu D-Q, Kalvakolanu DV. Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine [Internet]. 2017 [cited 2021 Nov 3];89:160–72. Available from: https://pubmed.ncbi.nlm.nih.gov/26778055/
Liu G, Wang M, He H, Li J. Doxorubicin-loaded tumor-targeting peptide-decorated polypeptide nanoparticles for treating primary Orthotopic Colon Cancer. Front Pharmacol. 2021;12:2687.
Gorain B, Choudhury H, Pandey M, Kesharwani P. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy. Mater Sci Eng C [Internet]. 2018 Oct 1 [cited 2019 Sep 7];91:868–80. Available from: https://www.sciencedirect.com/science/article/pii/S0928493117335713
Choudhury H, Gorain B, Pandey M, Kumbhar SA, Tekade RK, Iyer AK, et al. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int J Pharm. 2017;529(1–2):506–522. Available from: https://doi.org/10.1016/j.ijpharm.2017.07.018
Kesharwani P, Choudhury H, Meher JG, Pandey M, Gorain B. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Prog Mater Sci. 2019;103:484–508.
doi: 10.1016/j.pmatsci.2019.03.003
Rao W, Wang H, Han J, Zhao S, Dumbleton J, Agarwal P, et al. Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-like Cells. ACS Nano [Internet]. 2015 [cited 2021 Nov 3];9(6):5725–40. Available from: https://pubmed.ncbi.nlm.nih.gov/26004286/
Awan BN, Fatima N, Riaz S, Malik S, Ahmad W. Bacterial and liposomal vector guided drug delivery system via tumor markers carrier gene to treat neoplasm. J App Pharm. 2015;8:6.
Feng X, He P, Zeng C, Li Y-H, Das SK, Li B, et al. Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors (Review). Oncol Lett [Internet]. 2021 [cited 2021 Nov 3];21(2):1–1. Available from: http://www.spandidos-publications.com/10.3892/ol.2020.12371/abstract
Staedtke V, Roberts NJ, Bai R-Y, Zhou S. Clostridium novyi-NT in cancer therapy. Genes Dis [Internet]. 2016 [cited 2021 Nov 3];3(2):152. Available from: /pmc/articles/PMC6150096/.
Sedighi M, Bialvaei AZ, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med [Internet]. 2019 [cited 2021 Nov 3];8(6):3181. Available from: /pmc/articles/PMC6558487/.
Łukasiewicz K, Fol M. Microorganisms in the treatment of Cancer: advantages and limitations. J Immunol Res. 2018;2018:1–8.
doi: 10.1155/2018/2397808
Al-Hilu SA, Al-Shujairi WH. Dual role of Bacteria in carcinoma: stimulation and inhibition. Int J Microbiol. 2020;2020:1–15.
doi: 10.1155/2020/4639761
Gardlik R, Fruehauf JH. Bacterial vectors and delivery systems in cancer therapy. IDrugs [Internet]. 2010 Oct [cited 2019 Jan 10];13(10):701–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20878592 .
Mostaghaci B, Yasa O, Zhuang J, Sitti M. Bioadhesive bacterial microswimmers for targeted drug delivery in the urinary and gastrointestinal tracts. Adv Sci [Internet]. 2017 [cited 2021 Nov 3];4(6):170014. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201700058
Mi Z, Feng ZC, Li C, Yang X, Ma MT, Rong PF. Salmonella-mediated cancer therapy: an innovative therapeutic strategy. J Cancer. 2019;10(20):4765–76.
doi: 10.7150/jca.32650
Zhu C, Ji Z, Ma J, Ding Z, Shen J, Wang Q. Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment. Pharm 2021, Vol 13, Page 940 [Internet]. 2021 Jun 24 [cited 2021 Dec 17];13(7):940. Available from: https://www.mdpi.com/1999-4923/13/7/940/htm
Kojima M, Zhang Z, Nakajima M, Ooe K, Fukuda T. Construction and evaluation of bacteria-driven liposome. Sensors Actuators B Chem. 2013;183:395–400.
doi: 10.1016/j.snb.2013.03.127
Du NV, Han JW, Choi YJ, Cho S, Zheng S, Ko SY, et al. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella typhimurium). Sensors Actuators B Chem. 2016;224:217–24.
doi: 10.1016/j.snb.2015.09.034
Feng P, Cao Z, Wang X, Li J, Liu J. On-demand bacterial reactivation by restraining within a Triggerable Nanocoating. Adv Mater [Internet]. 2020 [cited 2021 Dec 17];32(34):2002406. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/adma.202002406
Sieow BFL, Wun KS, Yong WP, Hwang IY, Chang MW. Tweak to treat: reprograming Bacteria for Cancer treatment. Trends in Cancer. 2021;7(5):447–64.
doi: 10.1016/j.trecan.2020.11.004
Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019;25(7):1057.
doi: 10.1038/s41591-019-0498-z
Ho CL, Tan HQ, Chua KJ, Kang A, Lim KH, Ling KL, et al. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nat Biomed Eng. 2018;2(1):27–37.
doi: 10.1038/s41551-017-0181-y
Li R, Helbig L, Fu J, Bian X, Herrmann J, Baumann M, et al. Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy. Res Microbiol. 2019;170(2):74–9.
doi: 10.1016/j.resmic.2018.11.001
He L, Yang H, Liu F, Chen Y, Tang S, Ji W, et al. Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth. Oncotarget. 2017;8(49):85772–82.
doi: 10.18632/oncotarget.20486
He L, Yang H, Tang J, Liu Z, Chen Y, Lu B, et al. Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. J Biol Eng. 2019;13(1):58. Avaliable at: https://www.pubmed.ncbi.nlm.nih.gov/31297149/
Gurbatri CR, Lia I, Vincent R, Coker C, Castro S, Treuting PM, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020;12(530):eaax0876. Available at: https://www.pubmed.ncbi.nlm.nih.gov/32051224/
Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020;11(1):1–15.
doi: 10.1038/s41467-020-16602-0
Yoon W, Park YC, Kim J, Chae YS, Byeon JH, Min SH, et al. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma. Eur J Cancer. 2017;70:48–61.
doi: 10.1016/j.ejca.2016.10.010
Zheng JH, Nguyen VH, Jiang SN, Park SH, Tan W, Hong SH, et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017;9(376):eaak9537. Available at: https://www.pubmed.ncbi.nlm.nih.gov/28179508/
Liang K, Liu Q, Li P, Han Y, Bian X, Tang Y, et al. Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models. Cancer Gene Ther. 2018;25(7–8):167–83.
doi: 10.1038/s41417-018-0021-6
Din MO, Danino T, Prindle A, Skalak M, Selimkhanov J, Allen K, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nat. 2016;536(7614):81–5.
doi: 10.1038/nature18930
Lim D, Kim KS, Kim H-J, Ko K-C, Song JJ, Choi JH, et al. Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium. Oncotarget. 2017;8(23):37550–60.
doi: 10.18632/oncotarget.17197
Chen T, Zhao X, Ren Y, Wang Y, Tang X, Tian P, et al. Triptolide modulates tumour-colonisation and anti-tumour effect of attenuated Salmonella encoding DNase I. Appl Microbiol Biotechnol. 2019;103(2):929–39.
doi: 10.1007/s00253-018-9481-8
Kim K, Jeong JH, Lim D, Hong Y, Lim HJ, Kim GJ, et al. L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors. Mol Ther - Oncolytics. 2015;2:15007.
doi: 10.1038/mto.2015.7
Phan T, Nguyen VH, D’Alincourt MS, Manuel ER, Kaltcheva T, Tsai W, et al. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Ther. 2019;27(3):235–45.
doi: 10.1158/1535-7163.MCT-18-0768
Yoon W, Yoo Y, Chae YS, Kee SH, Kim BM. Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment. Ann Oncol. 2018;29(9):2010–7.
doi: 10.1093/annonc/mdy240
Zhao T, Wei T, Guo J, Wang Y, Shi X, Guo S, et al. PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide. Cell Death Dis. 2019;10(3):164. Available at: https://www.pubmed.ncbi.nlm.nih.gov/30778049/
Zhao C, He J, Cheng H, Zhu Z, Xu H. Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct. J Exp Clin Cancer Res. 2016;35(1):107. Available at: https://www.pubmed.ncbi.nlm.nih.gov/27371094/
Kitagawa K, Oda T, Saito H, Araki A, Gonoi R, Shigemura K, et al. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms’ tumor 1 protein. Cancer Immunol Immunother. 2017;66(6):787–98.
doi: 10.1007/s00262-017-1984-0
Wei C, Xun AY, Wei XX, Yao J, Wang JY, Shi RY, et al. Bifidobacteria expressing Tumstatin protein for antitumor therapy in tumor-bearing mice. Technol Cancer Res Treat. 2016;15(3):498–508.
doi: 10.1177/1533034615581977
Lv S, Wang X, Zhang N, Sun M, Qi W, Li Y, et al. Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer. Int J Oncol [Internet]. 2015 [cited 2021 Nov 5];46(3):1286–94. Available from: http://www.spandidos-publications.com/10.3892/ijo.2014.2812/abstract
James BR, Griffith TS. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic pathways in cancer immunosurveillance: molecular mechanisms and prospects for therapy. Res Reports Biochem [Internet]. 2014 [cited 2021 Nov 5];5:1–10. Available from: https://www.dovepress.com/tumor-necrosis-factor-related-apoptosis-inducing-ligand-induced-apopto-peer-reviewed-fulltext-article-RRBC
Setroikromo R, Zhang B, Reis CR, Mistry RH, Quax WJ. Death receptor 5 displayed on extracellular vesicles decreases TRAIL sensitivity of Colon Cancer cells. Front Cell Dev Biol. 2020;8:318.
doi: 10.3389/fcell.2020.00318
Daguenet E, Khalifa J, Tolédano A, Borchiellini D, Pointreau Y, Rodriguez-Lafrasse C, et al. To exploit the 5 ‘R’ of radiobiology and unleash the 3 ‘E’ of immunoediting: ‘RE’-inventing the radiotherapy-immunotherapy combination: https://doi.org/10.1177/1758835920913445 [Internet]. 2020 [cited 2021 Nov 5];12. Available from: https://journals.sagepub.com/doi/full/10.1177/1758835920913445
Stern C, Kasnitz N, Kocijancic D, Trittel S, Riese P, Guzman CA, et al. Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy. Int J cancer [Internet]. 2015 [cited 2021 Nov 5];137(8):2019–28. Available from: https://pubmed.ncbi.nlm.nih.gov/25868911/
Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, et al. Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. Oncoimmunology [Internet]. 2016 Jun 2 [cited 2021 Nov 5];5(6):e1130207. Available from: https://pubmed.ncbi.nlm.nih.gov/27471609/
Wrande M, Andrews-Polymenis H, Twedt DJ, Steele-Mortimer O, Porwollik S, McClelland M, et al. Genetic Determinants of Salmonella enterica Serovar Typhimurium Proliferation in the Cytosol of Epithelial Cells. Infect Immun [Internet]. 2016 [cited 2021 Nov 5];84(12):3517–26. Available from: https://pubmed.ncbi.nlm.nih.gov/27698022/
Sharrock AV, McManaway SP, Rich MH, Mumm JS, Hermans IF, Tercel M, et al. Engineering the Escherichia coli Nitroreductase NfsA to create a flexible enzyme-prodrug activation system. Front Pharmacol. 2021;12:1420.
doi: 10.3389/fphar.2021.701456
Kubiak AM, Minton NP. The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy. Res Microbiol. 2015;166(4):244–54.
doi: 10.1016/j.resmic.2014.12.006
Gao S, Jung J-H, Lin S-M, Jang A-Y, Zhi Y, Bum Ahn K, et al. Development of Oxytolerant Salmonella typhimurium Using Radiation Mutation Technology (RMT) for Cancer Therapy. Sci Reports 2020 101 [Internet]. 2020 [cited 2021 Nov 5];10(1):1–12. Available from: https://www.nature.com/articles/s41598-020-60396-6
Chien T, Doshi A, Danino T. Advances in bacterial cancer therapies using synthetic biology. Curr Opin Syst Biol [Internet]. 2017 Oct [cited 2021 Nov 3];5:1–8. Available from: https://pubmed.ncbi.nlm.nih.gov/29881788/
Sabzehali F, Azimi H, Goudarzi M. Bacteria as a vehicle in cancer therapy and drug delivery. Arch Adv Biosci [Internet]. 2017 [cited 2021 Nov 5];8(1):52–9. Available from: https://journals.sbmu.ac.ir/aab/article/view/13574
Raman V, Van Dessel N, Hall CL, Wetherby VE, Whitney SA, Kolewe EL, et al. Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases. Nat Commun 2021 121 [Internet]. 2021 [cited 2022 Mar 11];12(1):1–14. Available from: https://www.nature.com/articles/s41467-021-26367-9
Geng Z, Cao Z, Liu R, Liu K, Liu J, Tan W. Aptamer-assisted tumor localization of bacteria for enhanced biotherapy. Nat Commun 2021 121 [Internet]. 2021 [cited 2021 Dec 17];12(1):1–12. Available from: https://www.nature.com/articles/s41467-021-26956-8
Wang L, Cao Z, Zhang M, Lin S, Liu J. Spatiotemporally controllable distribution of combination therapeutics in solid tumors by dually modified Bacteria. Adv Mater [Internet]. 2021 [cited 2021 Dec 17];2106669. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/adma.202106669
Hajam IA, Dar PA, Won G, Lee JH. Bacterial ghosts as adjuvants: mechanisms and potential. Vet Res 2017 481 [Internet]. 2017 [cited 2021 Nov 5];48(1):1–13. Available from: https://veterinaryresearch.biomedcentral.com/articles/10.1186/s13567-017-0442-5
Haidinger W, Mayr UB, Szostak MP, Resch S, Lubitz W. Escherichia coli ghost production by expression of lysis gene E and staphylococcal nuclease. Appl Environ Microbiol [Internet]. 2003 [cited 2021 Nov 5];69(10):6113. Available from: /pmc/articles/PMC201253/.
Yu S, Peng W, Si W, Yin L, Liu S, Liu H, et al. Enhancement of bacteriolysis of Shuffled phage PhiX174 gene E. Virol J 2011 81 [Internet]. 2011 [cited 2021 Nov 5];8(1):1–6. Available from: https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-8-206
Schön P, Schrot G, Wanner G, Lubitz W, Witte A. Two-stage model for integration of the lysis protein E of ΦX174 into the cell envelope of Escherichia coli. FEMS Microbiol Rev [Internet]. 1995 [cited 2021 Nov 5];17(1–2):207–12. Available from: https://academic.oup.com/femsre/article/17/1-2/207/633535
Kudela P, Kollera VJ, Lubitz W. Bacterial ghosts (BGs)--advanced antigen and drug delivery system. Vaccine [Internet]. 2010 [cited 2021 Nov 5];28(36):5760–7. Available from: https://pubmed.ncbi.nlm.nih.gov/20619379/
Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv Drug Deliv Rev [Internet]. 2005 [cited 2021 Nov 5];57:1381–91. Available from: www.elsevier.com/locate/addr
Kudela P, Paukner S, Mayr UB, Cholujova D, Schwarczova Z, Sedlak J, et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother [Internet]. 2005 [cited 2021 Nov 5];28(2):136–43. Available from: https://pubmed.ncbi.nlm.nih.gov/15725957/
Ebensen T, Paukner S, Link C, Kudela P, de Domenico C, Lubitz W, et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol [Internet]. 2004 [cited 2021 Nov 5];172(11):6858–65. Available from: https://pubmed.ncbi.nlm.nih.gov/15153504/
Eko FO, Talin BA, Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum Vaccin [Internet]. 2008 [cited 2021 Nov 5];4(3):176–83. Available from: https://pubmed.ncbi.nlm.nih.gov/18382139/
Kudela P, Paukner S, Mayr UB, Cholujova D, Kohl G, Schwarczova Z, et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett [Internet]. 2008 [cited 2021 Nov 5];262(1):54–63. Available from: https://pubmed.ncbi.nlm.nih.gov/18164809/
Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release [Internet]. 2004 [cited 2021 Nov 6];94(1):63–74. Available from: https://pubmed.ncbi.nlm.nih.gov/14684272/
Groza D, Gehrig S, Kudela P, Holcmann M, Pirker C, Dinhof C, et al. Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. Oncoimmunology [Internet]. 2018 [cited 2021 Nov 5];7(5):e1424676. Available from: https://pubmed.ncbi.nlm.nih.gov/29721389/
Zhang Y, Ji W, He L, Chen Y, Ding X, Sun Y, et al. E. coli Nissle 1917-Derived Minicells for Targeted Delivery of Chemotherapeutic Drug to Hypoxic Regions for Cancer Therapy. Theranostics [Internet]. 2018 [cited 2021 Nov 6];8(6):1690–705. Available from: https://pubmed.ncbi.nlm.nih.gov/29556350/
Nguyen HN, Romero Jovel S, Nguyen THK. Nanosized Minicells Generated by Lactic Acid Bacteria for Drug Delivery. J Nanomater. 2017;2017:6847297.
doi: 10.1155/2017/6847297
S Song, Vuai MS, Zhong M. The role of bacteria in cancer therapy - enemies in the past, but allies at present. Infect Agent Cancer [Internet]. 2018 Mar 15 [cited 2021 Nov 6];13(1):9–18. Available from: https://pubmed.ncbi.nlm.nih.gov/29568324/
Rang CU, Proenca A, Buetz C, Shi C, Chao L. Minicells as a Damage Disposal Mechanism in Escherichia coli. mSphere [Internet]. 2018 [cited 2021 Nov 6];3(5):1–9. Available from: https://journals.asm.org/doi/abs/10.1128/mSphere.00428-18
Farley MM, Hu B, Margolin W, Liu J. Minicells, Back in Fashion. J Bacteriol [Internet]. 2016 [cited 2021 Nov 6];198(8):1186–95. Available from: https://pubmed.ncbi.nlm.nih.gov/26833418/
MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol [Internet]. 2009 [cited 2021 Nov 6];27(7):643–51. Available from: https://www.nature.com/articles/nbt.1547
Solomon BJ, Desai J, Rosenthal M, McArthur GA, Pattison ST, Pattison SL, et al. A first-time-in-human phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial Minicells. PLoS One [Internet]. 2015 [cited 2021 Nov 6];10(12):e0144559. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0144559
MacDiarmid JA, Langova V, Bailey D, Pattison ST, Pattison SL, Christensen N, et al. Targeted doxorubicin delivery to brain tumors via Minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS One [Internet] 2016 [cited 2021 Nov 6];11(4):e0151832. Available from: https://pubmed.ncbi.nlm.nih.gov/27050167/
MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RPP, et al. Bacterially derived 400 nm particles for encapsulation and Cancer cell targeting of chemotherapeutics. Cancer Cell. 2007;11(5):431–45.
doi: 10.1016/j.ccr.2007.03.012
Brahmbhatt H, MacDiarmid J. Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells. Vol. 433. 2010.
Fazal S, Lee R. Biomimetic bacterial membrane vesicles for drug delivery applications. Pharm 2021, Vol 13, Page 1430 [Internet]. 2021 [cited 2022 Feb 10];13(9):1430. Available from: https://www.mdpi.com/1999-4923/13/9/1430/htm
Coley WB. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891 [cited 2021 Dec 16];14(3):199–220. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1428624/
Miles B, Safran HP, Monk BJ. Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001. Gynecol Oncol Res Pract [Internet]. 2017 [cited 2021 Dec 16];4(1):10. Available from: https://pubmed.ncbi.nlm.nih.gov/28725449/
Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol [Internet]. 2002 [cited 2021 Dec 16];20(1):142–52. Available from: https://pubmed.ncbi.nlm.nih.gov/11773163/
Heimann DM, Rosenberg SA. Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. J Immunother [Internet]. 2003 [cited 2021 Dec 16];26(2):179–80. Available from: https://pubmed.ncbi.nlm.nih.gov/12616110/
Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-. Hum Gene Ther [Internet]. 2001 [cited 2021 Dec 16];12(12):1594–6. Available from: https://pubmed.ncbi.nlm.nih.gov/11529249/
Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med [Internet]. 2014 [cited 2021 Dec 16];6(249):249. Available from: https://pubmed.ncbi.nlm.nih.gov/25122639/
Duong MTQ, Qin Y, You SH, Min JJ. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med 2019 5112 [Internet]. 2019 [cited 2021 Dec 16];51(12):1–15. Available from: https://www.nature.com/articles/s12276-019-0297-0
Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003;10(10):737–44.
doi: 10.1038/sj.cgt.7700634
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy - Full Text View - ClinicalTrials.gov .
VNP20009 in Treating Patients With Advanced Solid Tumors - Tabular View - ClinicalTrials.gov .
Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria - Tabular View - ClinicalTrials.gov .
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread - Tabular View - ClinicalTrials.gov .
Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, et al. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology. 2018;7(4).
One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy - Tabular View - ClinicalTrials.gov .
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies - Tabular View - ClinicalTrials.gov .
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies - Tabular View - ClinicalTrials.gov .
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT - Full Text View - ClinicalTrials.gov .
Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325–33.
doi: 10.1200/JCO.2014.57.4244
Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical Cancer. Int J Gynecol Cancer. 2018;28(4):764–72.
doi: 10.1097/IGC.0000000000001235
Study of ADXS11–001 in Subjects With High Risk Locally Advanced Cervical Cancer - Tabular View - ClinicalTrials.gov .
Shende P, Basarkar V. Recent trends and advances in microbe-based drug delivery systems. DARU J Pharm Sci [Internet] 2019 [cited 2021 Dec 15];27(2):809. Available from: https://www.pmc/articles/PMC6895346/ .
Badie F, Ghandali M, Tabatabaei SA, Safari M, Khorshidi A, Shayestehpour M, et al. Use of Salmonella Bacteria in Cancer therapy: direct, drug delivery and combination approaches. Front Oncol. 2021;11:142.
doi: 10.3389/fonc.2021.624759
Ganeshpurkar A, Ganeshpurkar A, Pandey V, Agnihotri A, Bansal D, Dubey N. Harnessing the potential of bacterial ghost for the effective delivery of drugs and biotherapeutics. Int J Pharm Investig [Internet]. 2014 [cited 2021 Dec 15];4(1):10. Available from: https://www.pmc/articles/PMC3944611/ .
Chen H, Ji H, Kong X, Lei P, Yang Q, Wu W, et al. Bacterial ghosts-based vaccine and drug delivery systems. Pharm 2021, Vol 13, Page 1892 [Internet]. 2021 [cited 2021 Dec 15];13(11):1892. Available from: https://www.mdpi.com/1999-4923/13/11/1892/htm